The coronavirus disease with lung involvement is being associated with frequent morbidity and mortality. Since the receptor for advanced glycation end product (RAGE) pathway is considered as one of the most important determinants of physiological aging, healthcare companies are increasing the availability of treatment options. The RAGE pathway is considered to play an important role in the physiological aging and pathogenesis of lung diseases. This is creating revenue opportunities for stakeholders in the advanced glycation end products market.
It has been found that patients with high serum soluble-RAGE (sRAGE) levels are more likely to be exposed to COVID-19. Such findings are helping healthcare companies in the advanced glycation end products market to keep their economies running amid the ongoing pandemic due to the demand for treatment options. The availability of treatment products is important since the RAGE pathways play an important role in aggravation of COVID-19 in patients.
Advanced glycation end products (AGEs) is found to be involved in the pathogenesis of various diseases. AGEs play a critical role in the fibrosis and cirrhosis of CHC (chronic hepatitis C) patients through autophagy induction and hepatic stellate cells (HSC) activation. Since this process generates irreversible glycation end products, it induces cellular anomalies that result in potentially fatal clinical consequences. Such findings are translating into incremental opportunities for stakeholders in the advanced glycation end products market.
The glycation reaction in CHC patients tends to activate multiple cellular signals through different receptors, while their toxic by-products lead to acceleration of the pathogenesis of many disorders. Hence, stakeholders in the advanced glycation end products market are increasing their focus in treatments for CHC patients.
Alcohol is one of the most addictive substances consumed by billions of people and its excessive consumption has resulted in several diseases and injuries. However, there is lack of research pertaining the molecular mechanisms by which alcohol abuse causes cellular toxicity and organ damage. Hence, stakeholders in the advanced glycation end products market are increasing their R&D capabilities to derive the biological connection of AGE-alcohol-adduct formations to alcohol-mediated tissue injury.
Healthcare providers in hospitals, specialty clinics, and other facilities are helping patients to reduce the amounts of potentially harmful AGEs by decreasing the production of endogenous AGEs to prevent the possibility of several diseases. Since AGE adducts lead to alcohol-mediated multiorgan damage, stakeholders in the advanced glycation end products market are recommending patients to decrease the intake of n-6 fatty acids through dairy products, Western diets, and soft drinks, among others.
The advanced glycation end products market is projected to reach US$ 2.76 Bn by 2031. The high prevalence of type 1 and type 2 diabetes is acting as one of the key drivers for market growth. As such, ELISA and spectrofluorimetric methods are being used to determine the concentration of different AGEs and their receptors amongst diabetes patients. These methods are being used to study protein-bound AGEs, fluorescent low molecular weight AGEs and new class of melibiose-derived glycation product (MAGE).
Diabetes is directly related to the increasing prevalence of overweight and obese patients. Hence, stakeholders in the advanced glycation end products market are creating awareness about HbA1c as an important segment of long-term glycemic control and a reliable biomarker for the diagnosis of diabetes.
Stem cell-based regenerative therapies hold promising potentials for the treatment of a wide spectrum of diseases. However, it has been found that stem cell engraftment and survival are still challenging due to an unfavorable transplantation environment. Moreover, AGEs can add to the generation of these harmful conditions. Stakeholders in the advanced glycation end products market are increasing efforts to investigate solid scientific proof to derive new therapeutic insights into stem cell transplantation as an effective regenerative therapy.
It has been found that AGEs impair the proliferation and apoptosis on different types of primary stem cells in vitro. Stakeholders in the advanced glycation end products market are boosting their R&D capabilities to understand the effects of AGEs such as activation of RAGE or apoptopic pathways and even excessive ROS generation.
Diabetic and elderly patients often have musculoskeletal disorders that are linked with AGEs. Such findings are bolstering research activities in the advanced glycation end products market, as AGEs are a biomarker for ageing and evaluating disease conditions. However, apart from fluorescence, spectroscopy and immunological methods used to measure AGEs, there is a need for more standardized evaluation methods due to the heterogeneity of AGEs. Stakeholders in the market are increasing their research to improve these evaluation methods.
The AGE accumulation in neuromusculoskeletal tissues, including muscles, bones, and cartilages, among others tend to adversely affect biomechanical properties by causing charge changes and forming cross-linkages. Such findings are compelling stakeholders in the advanced glycation end products market to increase the availability of treatment options for patients with musculoskeletal disorders.
AGEs accumulate in vivo and activate various signaling pathways closely related to the occurrence of various chronic metabolic diseases. The high prevalence of these diseases are contributing to the growth of the advanced glycation end products market. AGEs play a pathological role in the development of metabolic diseases such as diabetes, Alzheimer’s, and atherosclerosis, among others. Hence, stakeholders in the market are providing treatments that help to reduce the endogenous formation and accumulation in vivo to prevent and control diabetes.
Companies in the advanced glycation end products market are developing strategies to target the formation of AGEs in vivo. They are increasing awareness about metformin that helps to reduce blood glucose levels and induces glyoxalase I activity, which ultimately reduces the level of methylglyoxal (MG), an important precursor of AGEs.
Analysts’ Viewpoint
Since the interaction of AGEs and their receptors (RAGE) cause inflammatory reactions and formation of blood clots in the walls of patients’ arteries, there is a need to improve effectiveness of treatments amid the COVID-19 pandemic. The advanced glycation end products market is predicted to expand at a CAGR of 5.4% during the forecast period. This is evident since there is a need for standardized evaluation methods to measure AGEs in patients with musculoskeletal disorders. Hence, stakeholders should increase efforts to understand AGEs related pathomechanism, which holds potential to develop novel methods for the prevention and therapy of such disorders that can affect patients’ quality of life.
Advanced Glycation End Products Market – Segmentation
TMR’s study on the global advanced glycation end products market includes information divided into four segments: type, application, end user, and region. Changing industry trends and other crucial market dynamics associated with these segments of the global advanced glycation end products market are discussed in detail.
| Type |
|
| Application |
|
| End User |
|
| Region |
|
Advanced glycation end products market to reach valuation Of US$ 2.76 Bn by 2031
Advanced glycation end products market is projected to expand at a CAGR of 5.4% from 2021 to 2031
Advanced glycation end products market is driven by high prevalence of diabetes in individuals
The non-fluorescent AGEs segment dominated the global advanced glycation end products market and the trend is likely to continue during the forecast period.
Key players operating in the global advanced glycation end products market include AbbVie, Inc. (Allergan Plc), Merck KGaA, Takeda Pharmaceutical Company Limited, Estée Lauder Companies, Shiseido Company
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Advanced Glycation End Products Market
4. Market Overview
4.1. Introduction
4.1.1. Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Advanced Glycation End Products Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Bioactivity of AGEs and RAGE: Flowchart
5.2. Key Trend Analysis
5.3. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)
6. Global Advanced Glycation End Products Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Advanced Glycation End Products Market Value Forecast, by Type, 2017–2031
6.3.1. Non-fluorescent AGEs
6.3.1.1. Carboxymethyl-lysine (CML)
6.3.1.2. Carboxyethyl-lysine (CEL)
6.3.1.3. Pyrraline
6.3.2. Fluorescent AGEs
6.3.2.1. Pentosidine
6.3.2.2. Methylglyoxal-lysine dimer (MOLD)
6.4. Global Advanced Glycation End Products Market Attractiveness, by Type
7. Global Advanced Glycation End Products Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Advanced Glycation End Products Market Value Forecast, by Application, 2017–2031
7.3.1. Diabetic Complications
7.3.2. Cancer
7.3.3. Bone Diseases
7.3.4. Neurodegenerative Diseases
7.3.5. Others
7.4. Global Advanced Glycation End Products Market Attractiveness, by Application
8. Global Advanced Glycation End Products Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Global Advanced Glycation End Products Market Value Forecast, by End-user, 2017–2031
8.3.1. Hospitals
8.3.2. Specialty Clinics
8.3.3. Others
8.4. Global Advanced Glycation End Products Market Attractiveness, by End-user
9. Global Advanced Glycation End Products Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Advanced Glycation End Products Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Global Advanced Glycation End Products Market Attractiveness, by Country/Region
10. North America Advanced Glycation End Products Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. North America Advanced Glycation End Products Market Value Forecast, by Type, 2017–2031
10.2.1. Non-fluorescent AGEs
10.2.1.1. Carboxymethyl-lysine (CML)
10.2.1.2. Carboxyethyl-lysine (CEL)
10.2.1.3. Pyrraline
10.2.2. Fluorescent AGEs
10.2.2.1. Pentosidine
10.2.2.2. Methylglyoxal-lysine dimer (MOLD)
10.3. North America Advanced Glycation End Products Market Value Forecast, by Application, 2017–2031
10.3.1. Diabetic Complications
10.3.2. Cancer
10.3.3. Bone Diseases
10.3.4. Neurodegenerative Diseases
10.3.5. Others
10.4. North America Advanced Glycation End Products Market Value Forecast, by End-user, 2017–2031
10.4.1. Hospitals
10.4.2. Specialty Clinics
10.4.3. Others
10.5. North America Advanced Glycation End Products Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. North America Advanced Glycation End Products Market Attractiveness Analysis
10.6.1. By Type
10.6.2. By Application
10.6.3. By End-user
10.6.4. By Country
11. Europe Advanced Glycation End Products Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Europe Advanced Glycation End Products Market Value Forecast, by Type, 2017–2031
11.2.1. Non-fluorescent AGEs
11.2.1.1. Carboxymethyl-lysine (CML)
11.2.1.2. Carboxyethyl-lysine (CEL)
11.2.1.3. Pyrraline
11.2.2. Fluorescent AGEs
11.2.2.1. Pentosidine
11.2.2.2. Methylglyoxal-lysine dimer (MOLD)
11.3. Europe Advanced Glycation End Products Market Value Forecast, by Application, 2017–2031
11.3.1. Diabetic Complications
11.3.2. Cancer
11.3.3. Bone Diseases
11.3.4. Neurodegenerative Diseases
11.3.5. Others
11.4. Europe Advanced Glycation End Products Market Value Forecast, by End-user, 2017–2031
11.4.1. Hospitals
11.4.2. Specialty Clinics
11.4.3. Others
11.5. Europe Advanced Glycation End Products Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Europe Advanced Glycation End Products Market Attractiveness Analysis
11.6.1. By Type
11.6.2. By Application
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Advanced Glycation End Products Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Asia Pacific Advanced Glycation End Products Market Value Forecast, by Type, 2017–2031
12.2.1. Non-fluorescent AGEs
12.2.1.1. Carboxymethyl-lysine (CML)
12.2.1.2. Carboxyethyl-lysine (CEL)
12.2.1.3. Pyrraline
12.2.2. Fluorescent AGEs
12.2.2.1. Pentosidine
12.2.2.2. Methylglyoxal-lysine dimer (MOLD)
12.3. Asia Pacific Advanced Glycation End Products Market Value Forecast, by Application, 2017–2031
12.3.1. Diabetic Complications
12.3.2. Cancer
12.3.3. Bone Diseases
12.3.4. Neurodegenerative Diseases
12.3.5. Others
12.4. Asia Pacific Advanced Glycation End Products Market Value Forecast, by End-user, 2017–2031
12.4.1. Hospitals
12.4.2. Specialty Clinics
12.4.3. Others
12.5. Asia Pacific Advanced Glycation End Products Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Asia Pacific Advanced Glycation End Products Market Attractiveness Analysis
12.6.1. By Type
12.6.2. By Application
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Advanced Glycation End Products Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Latin America Advanced Glycation End Products Market Value Forecast, by Type, 2017–2031
13.2.1. Non-fluorescent AGEs
13.2.1.1. Carboxymethyl-lysine (CML)
13.2.1.2. Carboxyethyl-lysine (CEL)
13.2.1.3. Pyrraline
13.2.2. Fluorescent AGEs
13.2.2.1. Pentosidine
13.2.2.2. Methylglyoxal-lysine dimer (MOLD)
13.3. Latin America Advanced Glycation End Products Market Value Forecast, by Application, 2017–2031
13.3.1. Diabetic Complications
13.3.2. Cancer
13.3.3. Bone Diseases
13.3.4. Neurodegenerative Diseases
13.3.5. Others
13.4. Latin America Advanced Glycation End Products Market Value Forecast, by End-user, 2017–2031
13.4.1. Hospitals
13.4.2. Specialty Clinics
13.4.3. Others
13.5. Latin America Advanced Glycation End Products Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Advanced Glycation End Products Market Attractiveness Analysis
13.6.1. By Type
13.6.2. By Application
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Advanced Glycation End Products Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Middle East & Africa Advanced Glycation End Products Market Value Forecast, by Type, 2017–2031
14.2.1. Non-fluorescent AGEs
14.2.1.1. Carboxymethyl-lysine (CML)
14.2.1.2. Carboxyethyl-lysine (CEL)
14.2.1.3. Pyrraline
14.2.2. Fluorescent AGEs
14.2.2.1. Pentosidine
14.2.2.2. Methylglyoxal-lysine dimer (MOLD)
14.3. Middle East & Africa Advanced Glycation End Products Market Value Forecast, by Application, 2017–2031
14.3.1. Diabetic Complications
14.3.2. Cancer
14.3.3. Bone Diseases
14.3.4. Neurodegenerative Diseases
14.3.5. Others
14.4. Middle East & Africa Advanced Glycation End Products Market Value Forecast, by End-user, 2017–2031
14.4.1. Hospitals
14.4.2. Specialty Clinics
14.4.3. Others
14.5. Middle East & Africa Advanced Glycation End Products Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Middle East & Africa Advanced Glycation End Products Market Attractiveness Analysis
14.6.1. By Type
14.6.2. By Application
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Share Analysis, by Company (2020)
15.2. Company Profiles
15.2.1. AbbVie, Inc. (Allergan Plc)
15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.1.2. Company Financials
15.2.1.3. Growth Strategies
15.2.1.4. SWOT Analysis
15.2.2. Merck KGaA
15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.2.2. Company Financials
15.2.2.3. Growth Strategies
15.2.2.4. SWOT Analysis
15.2.3. Takeda Pharmaceutical Company Limited
15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.3.2. Company Financials
15.2.3.3. Growth Strategies
15.2.3.4. SWOT Analysis
15.2.4. Estée Lauder Companies
15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.4.2. Company Financials
15.2.4.3. Growth Strategies
15.2.4.4. SWOT Analysis
15.2.5. Shiseido Company, Limited
15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.5.2. Company Financials
15.2.5.3. Growth Strategies
15.2.5.4. SWOT Analysis
15.2.6. Beiersdorf AG
15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.6.2. Company Financials
15.2.6.3. Growth Strategies
15.2.6.4. SWOT Analysis
15.2.7. L'Oréal S.A.
15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.7.2. Company Financials
15.2.7.3. Growth Strategies
15.2.7.4. SWOT Analysis
15.2.8. NuFACE
15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.8.2. Company Financials
15.2.8.3. Growth Strategies
15.2.8.4. SWOT Analysis
15.2.9. Rodan & Fields
15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.9.2. Company Financials
15.2.9.3. Growth Strategies
15.2.9.4. SWOT Analysis
15.2.10. PhotoMedex, Inc.
15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.10.2. Company Financials
15.2.10.3. Growth Strategies
15.2.10.4. SWOT Analysis
15.2.11. Ostium Cosmetics
15.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.11.2. Company Financials
15.2.11.3. Growth Strategies
15.2.11.4. SWOT Analysis
15.2.12. Cell Biolabs, Inc.
15.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.12.2. Company Financials
15.2.12.3. Growth Strategies
15.2.12.4. SWOT Analysis
15.2.13. Shanghai Korain Biotech Co., Ltd.
15.2.13.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.13.2. Company Financials
15.2.13.3. Growth Strategies
15.2.13.4. SWOT Analysis
List of Tables
Table 01: Global Advanced Glycation End Products Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 02: Global Advanced Glycation End Products Market Volume (Units) Forecast, by Non-fluorescent AGEs Type, 2017–2031
Table 03: Global Advanced Glycation End Products Market Volume (Units) Forecast, by Fluorescent AGEs Type, 2017–2031
Table 04: Global Advanced Glycation End Products Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 05: Global Advanced Glycation End Products Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 06: Global Advanced Glycation End Products Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 07: North America Advanced Glycation End Products Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 08: North America Advanced Glycation End Products Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 09: North America Advanced Glycation End Products Market Volume (Units) Forecast, by Non-fluorescent AGEs Type, 2017–2031
Table 10: North America Advanced Glycation End Products Market Volume (Units) Forecast, by Fluorescent AGEs Type, 2017–2031
Table 11: North America Advanced Glycation End Products Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 12: North America Advanced Glycation End Products Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 13: Europe Advanced Glycation End Products Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Europe Advanced Glycation End Products Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 15: Europe Advanced Glycation End Products Market Volume (Units) Forecast, by Non-fluorescent AGEs Type, 2017–2031
Table 16: Europe Advanced Glycation End Products Market Volume (Units) Forecast, by Fluorescent AGEs Type, 2017–2031
Table 17: Europe Advanced Glycation End Products Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 18: Europe Advanced Glycation End Products Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 19: Asia Pacific Advanced Glycation End Products Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 20: Asia Pacific Advanced Glycation End Products Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 21: Asia Pacific Advanced Glycation End Products Market Volume (Units) Forecast, by Non-fluorescent AGEs Type, 2017–2031
Table 22: Asia Pacific Advanced Glycation End Products Market Volume (Units) Forecast, by Fluorescent AGEs Type, 2017–2031
Table 23: Asia Pacific Advanced Glycation End Products Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 24: Asia Pacific Advanced Glycation End Products Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 25: Latin America Advanced Glycation End Products Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 26: Latin America Advanced Glycation End Products Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 27: Latin America Advanced Glycation End Products Market Volume (Units) Forecast, by Non-fluorescent AGEs Type, 2017–2031
Table 28: Latin America Advanced Glycation End Products Market Volume (Units) Forecast, by Fluorescent AGEs Type, 2017–2031
Table 29: Latin America Advanced Glycation End Products Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 30: Latin America Advanced Glycation End Products Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 31: Middle East & Africa Advanced Glycation End Products Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 32: Middle East & Africa Advanced Glycation End Products Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 33: Middle East & Africa Advanced Glycation End Products Market Volume (Units) Forecast, by Non-fluorescent AGEs Type, 2017–2031
Table 34: Middle East & Africa Advanced Glycation End Products Market Volume (Units) Forecast, by Fluorescent AGEs Type, 2017–2031
Table 35: Middle East & Africa Advanced Glycation End Products Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 36: Middle East & Africa Advanced Glycation End Products Market Value (US$ Mn) Forecast, by End-user, 2017–2031
List of Figures
Figure 01: Global Advanced Glycation End Products Market Value (US$ Mn) and Y-O-Y Growth (%) Forecast, 2017–2031
Figure 02: Global Advanced Glycation End Products Market Value Share, by Region, 2020
Figure 03: Global Advanced Glycation End Products Market Value Share Analysis, by Type, 2020 and 2031
Figure 04: Global Advanced Glycation End Products Market Value (US$ Mn), Non-fluorescent AGEs, 2017–2031
Figure 05: Global Advanced Glycation End Products Market Value (US$ Mn), Fluorescent AGEs, 2017–2031
Figure 06: Global Advanced Glycation End Products Market Attractiveness Analysis, by Type, 2021-2031
Figure 07: Global Advanced Glycation End Products Market Value Share Analysis, by Application, 2020 and 2031
Figure 08: Global Advanced Glycation End Products Market Value (US$ Mn), by Diabetic Complications, 2017–2031
Figure 09: Global Advanced Glycation End Products Market Value (US$ Mn), Cancer, 2017–2031
Figure 10: Global Advanced Glycation End Products Market Value (US$ Mn), by Bone Diseases, 2017–2031
Figure 11: Global Advanced Glycation End Products Market Value (US$ Mn), Neurodegenerative Diseases, 2017–2031
Figure 12: Global Advanced Glycation End Products Market Value (US$ Mn), by Others, 2017–2031
Figure 13: Global Advanced Glycation End Products Market Attractiveness Analysis, by Application, 2021–2031
Figure 14: Global Advanced Glycation End Products Market Value Share Analysis, by End-user, 2020 and 2031
Figure 15: Global Advanced Glycation End Products Market Value (US$ Mn), by Hospitals, 2017–2031
Figure 16: Global Advanced Glycation End Products Market Value (US$ Mn), Specialty Clinics , 2017–2031
Figure 17: Global Advanced Glycation End Products Market Value (US$ Mn), by Others, 2017–2031
Figure 18: Global Advanced Glycation End Products Market Attractiveness Analysis, by End-user, 2021–2031
Figure 19: Global Advanced Glycation End Products Market Value Share Analysis, by Region, 2020 and 2031
Figure 20: Global Advanced Glycation End Products Market Attractiveness Analysis, by Region
Figure 21: North America Advanced Glycation End Products Market Value (US$ Mn) Forecast Projection, 2017–2031
Figure 22: North America Advanced Glycation End Products Market Value Share (%), by Country, 2020 and 2031
Figure 23: North America Advanced Glycation End Products Market Attractiveness, by Country, 2021–2031
Figure 24: North America Advanced Glycation End Products Market Value Share Analysis, by Type, 2020 and 2031
Figure 25: North America Advanced Glycation End Products Market Attractiveness, by Type, 2021–2031
Figure 26: North America Advanced Glycation End Products Market Value Share Analysis, by Application, 2020 and 2031
Figure 27: North America Advanced Glycation End Products Market Attractiveness, by Application, 2021–2031
Figure 28: North America Advanced Glycation End Products Market Value Share Analysis, by End-user, 2020 and 2031
Figure 29: North America Advanced Glycation End Products Market Attractiveness, by End-user, 2021–2031
Figure 30: Europe Advanced Glycation End Products Market Value (US$ Mn) Forecast Projection, 2017–2031
Figure 31: Europe Advanced Glycation End Products Market Value Share (%), by Country/Sub-region, 2020 and 2031
Figure 32: Europe Advanced Glycation End Products Market Attractiveness, by Country/Sub-region, 2021–2031
Figure 33: Europe Advanced Glycation End Products Market Value Share Analysis, by Type, 2020 and 2031
Figure 34: Europe Advanced Glycation End Products Market Attractiveness, by Type, 2021–2031
Figure 35: Europe Advanced Glycation End Products Market Value Share Analysis, by Application, 2020 and 2031
Figure 36: Europe Advanced Glycation End Products Market Attractiveness, by Application, 2021–2031
Figure 37: Europe Advanced Glycation End Products Market Value Share Analysis, by End-user, 2020 and 2031
Figure 38: Europe Advanced Glycation End Products Market Attractiveness, by End-user, 2021–2031
Figure 39: Asia Pacific Advanced Glycation End Products Market Value (US$ Mn) Forecast Projection, 2017–2031
Figure 40: Asia Pacific Advanced Glycation End Products Market Value Share (%), by Country, 2020 and 2031
Figure 41: Asia Pacific Advanced Glycation End Products Market Attractiveness, by Country/Sub-region, 2021–2031
Figure 42: Asia Pacific Advanced Glycation End Products Market Value Share Analysis, by Type, 2020 and 2031
Figure 43: Asia Pacific Advanced Glycation End Products Market Attractiveness, by Type, 2021–2031
Figure 44: Asia Pacific Advanced Glycation End Products Market Value Share Analysis, by Application, 2020 and 2031
Figure 45: Asia Pacific Advanced Glycation End Products Market Attractiveness, by Application, 2021–2031
Figure 46: Asia Pacific Advanced Glycation End Products Market Value Share Analysis, by End-user, 2020 and 2031
Figure 47: Asia Pacific Advanced Glycation End Products Market Attractiveness, by End-user, 2021–2031
Figure 48: Latin America Advanced Glycation End Products Market Revenue (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 49: Latin America Advanced Glycation End Products Market Value Share (%), by Country/Sub-region, 2020 and 2031
Figure 50: Latin America Advanced Glycation End Products Market Attractiveness, by Country, 2021–2031
Figure 51: Latin America Advanced Glycation End Products Market Value Share Analysis, by Type, 2020 and 2031
Figure 52: Latin America Advanced Glycation End Products Market Attractiveness, by Type, 2021–2031
Figure 53: Latin America Advanced Glycation End Products Market Value Share Analysis, by Application, 2020 and 2031
Figure 54: Latin America Advanced Glycation End Products Market Attractiveness, by Application, 2021–2031
Figure 55: Latin America Advanced Glycation End Products Market Value Share Analysis, by End-user, 2020 and 2031
Figure 56: Latin America Advanced Glycation End Products Market Attractiveness, by End-user, 2021–2031
Figure 57: Middle East & Africa Advanced Glycation End Products Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 58: Middle East & Africa Advanced Glycation End Products Market Value Share, by Country/Sub-region, 2020–2031
Figure 59: Middle East & Africa Advanced Glycation End Products Market Attractiveness, by Country/Sub-region, 2021–2031
Figure 60: Middle East & Africa Advanced Glycation End Products Market Value Share Analysis, by Type, 2020 and 2031
Figure 61: Middle East & Africa Advanced Glycation End Products Market Attractiveness, by Type, 2021–2031
Figure 62: Middle East & Africa Advanced Glycation End Products Market Value Share Analysis, by Application, 2020 and 2031
Figure 63: Middle East & Africa Advanced Glycation End Products Market Attractiveness, by Application, 2021–2031
Figure 64: Middle East & Africa Advanced Glycation End Products Market Value Share Analysis, by End-user, 2020 and 2031
Figure 65: Middle East & Africa Advanced Glycation End Products Market Attractiveness, by End-user, 2021–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Advanced Glycation End Products Market Insights, 2021-2031
